Digital Therapeutics & DTx

34 confirmed failures

Funding Burned

$298.5M

Median Lifespan

9 years

Dominant Failure

Clinical Validation Gap

50% of cases

Period

2010 — 2024

Failure Pattern Distribution

Couldn't prove the product worked17 (50%)

Couldn't get paid by insurance12 (35%)

Outspent by bigger competitors2 (6%)

Customer acquisition costs too high1 (3%)

Regulation moved faster than the company1 (3%)

Sold through the wrong channel1 (3%)

Curator's Note

auto-generated

This section of the registry contains 34 healthcare Digital Therapeutics & DTx startups that shut down between 2010 and 2024, representing $298.5M in combined funding. The dominant failure pattern is Clinical Validation Gap (50% of cases). Reimbursement Dependency accounts for another 35%. These entries were coded using the Gioia three-level qualitative methodology. Inter-rater reliability: 0.82 (strong agreement). This note is auto-generated and will be replaced by editorial analysis.

Have a correction? Reach out.

Sample verdict

pre-rendered

Based on 41 Digital Therapeutics & DTx failures in the corpus. Not your thesis.

KILLEDKill threshold 74%

Couldn't prove the product worked

Buyers need proof your product works, and you do not have it yet.

Precedents

Ieso Digital Health (HC-0061) · 2023
Twill (Happify Health) (HC-0065) · 2024
Mahana Therapeutics (HC-0105) · 2022

Run this against your thesis →

Cost of Inaction

Cost of Inaction — Workflow Cost

Your workflow area

Hours/week spent on this workflow

Cost of Inaction — Startup Risk

Your vertical

Funding stage

Target runway (months)

Building in digital therapeutics & dtx? Stress-test your thesis against these 34 failures.